Kostas Biliouris
Stock Analyst at BMO Capital
(1.14)
# 3,457
Out of 4,712 analysts
47
Total ratings
32.5%
Success rate
-12.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTA Centessa Pharmaceuticals | Maintains: Outperform | $20 → $35 | $16.90 | +107.10% | 6 | Sep 16, 2024 | |
| MGX Metagenomi | Maintains: Outperform | $22 → $17 | $3.77 | +350.93% | 2 | Aug 15, 2024 | |
| IONS Ionis Pharmaceuticals | Downgrades: Market Perform | $67 → $60 | $36.53 | +64.25% | 1 | Aug 2, 2024 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $63 → $40 | $5.81 | +588.47% | 4 | Jul 18, 2024 | |
| LEGN Legend Biotech | Maintains: Outperform | $90 | $32.80 | +174.39% | 3 | Jul 3, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $234 | $243.25 | -3.80% | 4 | Jun 24, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $170 → $200 | $121.90 | +64.07% | 4 | Jun 24, 2024 | |
| KRRO Korro Bio | Maintains: Outperform | $120 | $43.30 | +177.14% | 3 | May 15, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $62 → $70 | $12.05 | +480.91% | 5 | May 10, 2024 | |
| BEAM Beam Therapeutics | Maintains: Outperform | $57 | $28.81 | +97.85% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $37 | $28.53 | +29.69% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $67 | $7.00 | +857.14% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $100 | $66.63 | +50.08% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $2.76 | +588.41% | 1 | Oct 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $210 → $120 | $4.50 | +2,566.67% | 2 | Mar 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $62 | $5.77 | +974.52% | 2 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $98 | $40.94 | +139.37% | 1 | Jun 17, 2022 |
Centessa Pharmaceuticals
Sep 16, 2024
Maintains: Outperform
Price Target: $20 → $35
Current: $16.90
Upside: +107.10%
Metagenomi
Aug 15, 2024
Maintains: Outperform
Price Target: $22 → $17
Current: $3.77
Upside: +350.93%
Ionis Pharmaceuticals
Aug 2, 2024
Downgrades: Market Perform
Price Target: $67 → $60
Current: $36.53
Upside: +64.25%
4D Molecular Therapeutics
Jul 18, 2024
Maintains: Outperform
Price Target: $63 → $40
Current: $5.81
Upside: +588.47%
Legend Biotech
Jul 3, 2024
Maintains: Outperform
Price Target: $90
Current: $32.80
Upside: +174.39%
Alnylam Pharmaceuticals
Jun 24, 2024
Maintains: Outperform
Price Target: $234
Current: $243.25
Upside: -3.80%
Sarepta Therapeutics
Jun 24, 2024
Maintains: Outperform
Price Target: $170 → $200
Current: $121.90
Upside: +64.07%
Korro Bio
May 15, 2024
Maintains: Outperform
Price Target: $120
Current: $43.30
Upside: +177.14%
Intellia Therapeutics
May 10, 2024
Maintains: Outperform
Price Target: $62 → $70
Current: $12.05
Upside: +480.91%
Beam Therapeutics
Mar 27, 2024
Maintains: Outperform
Price Target: $57
Current: $28.81
Upside: +97.85%
Jan 31, 2024
Initiates: Market Perform
Price Target: $37
Current: $28.53
Upside: +29.69%
Jan 31, 2024
Initiates: Outperform
Price Target: $67
Current: $7.00
Upside: +857.14%
Nov 3, 2023
Maintains: Outperform
Price Target: $102 → $100
Current: $66.63
Upside: +50.08%
Oct 9, 2023
Initiates: Outperform
Price Target: $19
Current: $2.76
Upside: +588.41%
Mar 14, 2023
Downgrades: Market Perform
Price Target: $210 → $120
Current: $4.50
Upside: +2,566.67%
Jul 18, 2022
Maintains: Outperform
Price Target: $48 → $62
Current: $5.77
Upside: +974.52%
Jun 17, 2022
Initiates: Outperform
Price Target: $98
Current: $40.94
Upside: +139.37%